已收盘 10-16 16:00:00 美东时间
0.000
0.00%
Pasithea Therapeutics Corp. announced that an abstract detailing the Phase 1 dose-escalation study of PAS-004, a next-generation macrocyclic MEK inhibitor, in patients with MAPK pathway-driven advanced solid tumors, has been accepted for poster presentation at the ESMO Congress 2026. The presentation will occur on Friday, October 23, 2026, and the full abstract will be published on the ESMO website under the congress' embargo policy. PAS-004 is b...
07-21 11:00
While Biogen (BIIB) traded lower after reporting detailed results from a mid-stage trial for its new Alzheimer’s drug, diranersen, developed with Ionis Pharmaceuticals (IONS), patient advocates were u...
07-14 23:26
DeFi Development Corp. (DFDV) announced the transition of leadership for DisclaimerCoin (DONT) to Daniel Reis-Faria, CEO of ZeroStack Holdings Inc., and his team. This shift aims to accelerate ecosystem growth, partnerships, and utility for DONT. DFDV and ZeroStack have a prior relationship focused on Solana adoption. Reis-Faria brings extensive blockchain and digital asset experience. DFDV will retain 31.6% of DONT's supply in its treasury, whil...
07-08 13:00
Stantec (STN) said late Wednesday that Gord Johnston will retire as President and CEO effective October 1 but will remain on the board as vice chair. Susan Reisbord, currently COO of the company's Nor...
06-18 21:21
Stantec announced that Gord Johnston will retire as CEO effective October 1, and Susan Reisbord, current COO of North America, will succeed him. This transition follows a Board-led succession plan, ensuring continuity in client relationships and operations. Reisbord, with over 30 years of industry experience, joined Stantec in 2021 via the Cardno acquisition. Johnston praised Reisbord's leadership and expressed confidence in the company's future ...
06-17 21:00
Pasithea Therapeutics Corp. will participate in the Children's Tumor Foundation's 2026 NF Conference in Denver, Colorado, to engage with the NF1 community following FDA Fast Track and Rare Pediatric Disease Designations for its lead treatment candidate PAS-004. The company aims to develop safer, long-term therapies for NF1 patients and encourages participants to contact them in advance for meetings. PAS-004 is a next-generation macrocyclic MEK in...
06-15 11:02
Magnera Corporation has sold its Caerphilly, UK operations, which produce metallized paper for premium labels, gift wrap, and food packaging, to Polyart Group, a Prudentia Capital holding. Magnera CEO Curt Begle thanked the Caerphilly team and emphasized commitment to a seamless transition for customers. Dominik Zwerger of Prudentia Capital expressed excitement about adding the operations to their portfolio and leveraging the management team's ex...
06-15 06:00
Caleres (NYSE:CAL) held its first-quarter earnings conference call on Thursday....
06-04 22:47
The latest update is out from Origin Enterprises plc ( ($GB:OGN) ). Origin Ente...
06-03 22:05